The University of Ottawa trial infuses MSCs to reduce inflammation in the central nervous systems of MS patients.
The Multiple Sclerosis Society of Canada has funded Canada’s first stem cell clinical trial to treat multiple sclerosis, conducted by researchers at the University of Ottawa. The trial, called MESCAMS [Mesenchymal Stem Cell Therapy for Canadian MS patients], will comprise MSC infusions to the central nervous system to utilize their ability to regulate autoimmune attacks and reduce inflammation in 40 MS patients. Continue reading →
A five year phase II clinical trial has shown initial success in treating multiple sclerosis.
In a recent update of an ongoing five year clinical trial conducted by the Chicago Blood Cancer Institute, patients with relapsing-remitting multiple sclerosis have experienced suppression of disease-related inflammation as a result of hematopoietic stem cell transplantations. The stem cells have the ability to regulate the autoimmune attack on the central nervous system, and have provided 82.8% of the patients with two years thus far of event-free disease remission. Continue reading →
Neurons in patients with MS are attacked by the immune system
A team of researchers led by Dr. Cecilia Laterza and Dr. Gianvito Martino at the San Raffaele Hospital have found a novel use of neural stem cells to modulate damage caused by multiple sclerosis. Stem cells injected into mice with MS travelled to sites of inflammation and secreted factors to promote growth of myelin-producing cells and limit the inflammation caused by the strong immune attack.